Forbion
Forbion is a specialist life-sciences investment firm with deep roots in European biotechnology and an increasingly international platform.
- Healthcare and biotechnology venture capital investor
- Healthcare & BioTech Venture Capital
- Tier II
Overview
Forbion is a specialist life-sciences investment firm with deep roots in European biotechnology and an increasingly international platform. It invests across therapeutics and related medical innovation from company formation and venture stages through later private-market development.
The firm is particularly relevant to companies that need to connect European scientific assets with US capital, pharmaceutical relationships, clinical-development expertise, and global commercialization pathways. Its team and office network support cross-border company building rather than purely regional investing. Within The Economy Wiki, the institution is connected to the Healthcare & Biotechnology Venture Capital market category.
Firm facts
| Institution | Forbion |
| Type | Healthcare and biotechnology venture capital investor |
| Headquarters | Naarden / Amsterdam / Munich / Boston / Singapore, Netherlands / Germany / United States / Singapore |
| Founded | 2006 |
| Primary ranking focus | Healthcare & BioTech Venture Capital |
| Highest 2026 tier | Tier II |
Activities and investment capabilities
Forbion operates within life-sciences innovation, clinical development and healthcare company building. Its category-specific capabilities are summarized below.
Life-sciences investing
Capital for therapeutics, diagnostics, medical devices and research platforms.
Clinical development
Support across scientific validation, trials, regulation and commercialization.
Healthcare innovation
Investment in care delivery, health technology and data-enabled medical businesses.
Strategy and market coverage
Stage and strategy coverage
Company formation through growth; translational research; clinical and commercial financing
Sector and market coverage
Biotechnology; therapeutics; diagnostics; medtech; digital health and healthcare services
Market position
Forbion fits Tier II because its specialist authority, institutional scale, European leadership, and active international expansion make it one of the strongest life-sciences venture platforms outside the United States.
Forbion is assessed within the Healthcare & Biotechnology Venture Capital framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
Forbion is recognized Tier II in Top 30 Healthcare & BioTech Venture Capital 2026. The rankings compare institutions by market relevance, investment or operating capability, sector and stage expertise, institutional credibility and current activity. Comparable links support navigation and do not imply that every institution competes for every company, fund commitment or transaction.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through the institution’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to Forbion as the public-facing organization. Individual funds, management companies, advisers, lending entities, broker-dealers and regulated affiliates may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | Forbion |
| Headquarters | Naarden / Amsterdam / Munich / Boston / Singapore, Netherlands / Germany / United States / Singapore |
| Public website | forbion.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the venture, financing, diligence and private-market themes relevant to this institution:
- The Mid-Market Advantage in Healthcare Private Equity
- Growth Equity vs Venture Capital and Buyouts: Key Differences
- Private Equity Technology Due Diligence in the AI Era
